Intilin-P Tablet is a combination pharmaceutical formulation containing Citicoline 500 mg and Piracetam 800 mg, designed to enhance cognitive function and support neurological health. Citicoline, a neuroprotective agent, serves as a precursor for the biosynthesis of phosphatidylcholine, an essential component of neuronal membranes, thereby promoting membrane repair and improving neurotransmitter synthesis. Piracetam, a nootropic agent, modulates neuronal and vascular functions, enhancing cerebral blood flow and neuroplasticity. Together, these active ingredients synergistically improve memory, attention, and learning capacity, making Intilin-P suitable for managing cognitive impairments associated with stroke, dementia, traumatic brain injury, and other neurodegenerative conditions. The tablet is indicated for patients experiencing memory deficits, age-related cognitive decline, and cerebrovascular insufficiency. Intilin-P is generally well tolerated; however, it should be used under medical supervision, particularly in individuals with hypersensitivity to its components or underlying renal impairment. Dosage and duration of therapy should be individualized based on clinical response and patient condition. This combination therapy represents a valuable option in neurorehabilitation and cognitive enhancement protocols, contributing to improved quality of life in affected patients.